Navigation Links
ViroPharma Announces Approval of Modernized Labeling for Vancocin® (vancomycin hydrochloride, USP) Capsules
Date:12/14/2011

Vancocin.  Assessment of auditory function may be appropriate in some instances.  Prescribing Vancocin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug resistant bacteria.  In clinical trials, the most common adverse reactions (greater than or equal to 10 percent) were nausea (17 percent), abdominal pain (15 percent), and hypokalemia (13 percent).  Patients over 65 years of age may take longer to respond to therapy compared to patients less than 65 years of age.  Clinicians should be aware of the importance of appropriate duration of Vancocin treatment in patients over 65 years of age and not discontinue or switch to alternative treatment prematurely. 

For Vancocin prescribing information, please visit http://www.viropharma.com/products/vancocin.aspx

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing novel solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options, including C1 esterase inhibitor deficiency, treatment of seizures in children and adolescents, adrenal insufficiency, and C. difficile-associated diarrhea (CDAD).  Our goal is to provide rewarding careers to employees, to create new standards of care in the way serious diseases are treated, and to build international partnerships with the patients, advocates, and health care professionals we serve.  ViroPharma's commercial products address diseases including hereditary angioedema (HAE), seizures in children and adolescents, and CDAD; for full U.S. prescribing information on our products, please download the package inserts at

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. ViroPharma to Present at Three Upcoming Healthcare Conferences
2. ViroPharma to Present at the Natixis Bleichroeder Conference
3. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
5. ViroPharma Announces Discontinuation of HCV-796 Development
6. ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
7. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
8. ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
9. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
10. ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
11. ViroPharma Incorporated Reports Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 23, 2013  Spring Bank Pharmaceuticals, Inc., a biopharmaceutical ... infections, today announced that it has initiated dosing in ... once daily, oral therapy for the treatment of HCV ... and is designed to assess both the safety and ... first-in-class drug for the treatment of chronic HCV infections ...
(Date:5/23/2013)... FREDERICK, Md. , May 23, 2013  BioElectronics ... safe consumer medical devices, comments on the FDA panel ... Public Advisory Panel Reclassification – Pulsed Shortwave Therapy Meeting ... Gaithersburg, MD , USA.  The focus of the ... instructed the panel to focus solely on the application ...
(Date:5/23/2013)... , May 23, 2013 Halozyme Therapeutics, ... the appointment of David A. Ramsay ... was most recently Vice President, Corporate Development at ... "With his established financial management experience ... by working in our commercial group for the ...
Breaking Medicine Technology:Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 2Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 3BioElectronics and Pulsed Shortwave Therapy Make Progress 2Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer 2
... (Nasdaq: KNDL ), a leading, global full-service ... its Annual Meeting of Shareholders due to its merger ... been scheduled for May 19, 2011, in Cincinnati, Ohio. ... a merger agreement with INC Research.  The merger transaction ...
... A new device designed to assist blood circulation ... coronary intervention (PCI) has shown improved outcomes compared to ... of the PROTECT II study were presented as a ... Sessions in Baltimore. These devices decrease ...
Cached Medicine Technology:Kendle Announces Postponement of 2011 Annual Meeting 2Kendle Announces Postponement of 2011 Annual Meeting 3Kendle Announces Postponement of 2011 Annual Meeting 4New Device to Support Blood Circulation for Heart Patients Shows Improved Outcomes Compared to Current Treatment 2
(Date:5/24/2013)... The leading retail brand Short Dresses ... prom dresses . Now that is quite unbelievable, especially in ... brand name since its origin. The retailer has already revealed ... this huge discount offer will be an added bonanza for ... privileged to announce that Short Dresses is to offer different ...
(Date:5/23/2013)... NY (PRWEB) May 24, 2013 Magnatag’s ... employee absentee patterns and reduces vacation conflicts. A Manufacturing ... problem with vacation conflicts; now employees and managers can ... have any problems. Attendance is important to us and ... are exposed. That may seem harsh but it has ...
(Date:5/23/2013)... May 24, 2013 Sublime Beauty® ... Cellulite Whisperer line, with a 35% discount ... Sale" includes two proprietary products, the Cellulite ... . , Purchasers receive a report "Getting Control ... Gel has a wonderful grapefruit scent," says Kathy ...
(Date:5/23/2013)... -- High blood glucose is associated with poor outcomes ... (IIT) to control hyperglycemia is a common practice in ... consistent benefit and even shows harms associated with the ... Physicians, (ACP) Clinical Guidelines Committee in a new evidence-based ... of Medical Quality . , "Clinicians caring for hospitalized ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Whether working ... Operations Forces and law enforcement need an added layer ... Security Enhancer, Night VISER , is an effective ... motion sensing system to increase border and perimeter security. ... VISER have more than tripled over the past three ...
Breaking Medicine News(10 mins):Health News:short prom dresses Offers Abnormally Low Discount on Its New Collections 2Health News:New Attendance, Vacation and Training Tracker Board Reduces Employee Conflicts and Improves Attendance 2Health News:Fresh Organics in the New Cellulite Whisperer® Products from Sublime Beauty®; "Get Ready for Summer Sale" Continues 2Health News:ACP issues recommendations for management of high blood glucose in hospitalized patients 2Health News:Lighting Up the Night: ARA Announces Record Sales of Its Night VISER System 2Health News:Lighting Up the Night: ARA Announces Record Sales of Its Night VISER System 3
... , This release is available in German . ... encoding data at a rate of 26 terabits per second on ... km, and decoding them successfully. This is the largest data volume ... allows to transmit the contents of 700 DVDs in one second ...
... Mount Sinai School of Medicine have discovered a protein signaling ... medications to inhibit this pathway may be effective in the ... the current issue of the journal Cancer Cell . ... Jack and Jane B. Aron Professor and Chairman of the ...
... a number from the University of North Carolina at Chapel ... that contribute to the debilitating lung disease that is the ... into the causes of the wide variation in lung disease ... to new diagnostic markers and therapeutic approaches for this and ...
... , SUNDAY, May 22 (HealthDay News) -- New Swedish ... of major cardiovascular complications among patients who have ... finding builds on earlier work that was published by ... fall. That study suggested that Inspra (eplerenone), an aldosterone ...
... has found that allowing full access to personal medical ... cancer patients. Published early online in Cancer , ... study indicates that providing accurate information to patients through ... communication with their physicians. Most cancer patients say ...
... Hospital for Special Surgery in New York has shown that ... suppress aspects of inflammation. The researchers say the identification of ... new treatments for diseases such as rheumatoid arthritis. The study ... the journal Nature Immunology . "Prior to this ...
Cached Medicine News:Health News:World record in ultra-rapid data transmission 2Health News:Mount Sinai researchers discover possible new target for sarcoma treatment and prevention 2Health News:Consortium identifies genome regions that could influence severity of cystic fibrosis 2Health News:Consortium identifies genome regions that could influence severity of cystic fibrosis 3Health News:Blood Pressure Drug Helps Those With Mild Heart Failure 2Health News:Access to personal medical records increases satisfaction among new cancer patients 2Health News:Study identifies novel role for a protein that could lead to new treatments for rheumatoid arthritis 2Health News:Study identifies novel role for a protein that could lead to new treatments for rheumatoid arthritis 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: